Long-Term Survival and Gradual Recovery of B Cells in Patients with Refractory Large B Cell Lymphoma Treated with Axicabtagene Ciloleucel (Axi-Cel)

Jacobson, Caron A.; Locke, Frederick L.; Ghobadi, Armin; Miklos, David B.; Lekakis, Lazaros J.; Oluwole, Olalekan O.; Lin, Yi; Braunschweig, Ira; Hill, Brian T.; Timmerman, John M.; Deol, Abhinav; Reagan, Patrick M.; Stiff, Patrick J.; Flinn, Ian W.; Farooq, Umar; Goy, André; McSweeney, Peter A.; Muñoz, Javier; Siddiqi, Tanya; Rossi, John M.; Bot, Adrian; Zheng, Lianqing; Vezan, Remus; Bashir, Zahid; Kim, Jaeyeon; Chu, Rong; Neelapu, Sattva S.

doi:10.1182/blood-2020-134362

Cited by 26 publications

(37 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The authors concluded that MCMs better predicted Kaplan-Meier data available from the updated ZUMA-1 trial published in 2018 [55]. Following the presentation of this validation exercise, more recent ZUMA-1 trial data, with median follow-up of 39.1 months and with a median OS of 25.8 months, were presented at ASH 2020 [66]. Continuing to re-evaluate the appropriateness of survival extrapolation techniques using the most recent clinical trial extension data will serve to strengthen survival analyses and its outputs.…”

Section: Opportunities For Future Researchmentioning

confidence: 99%

“…Continuing to re-evaluate the appropriateness of survival extrapolation techniques using the most recent clinical trial extension data will serve to strengthen survival analyses and its outputs. As a result, follow-on analyses to our qualitative assessment could compare extrapolated survival data from early clinical trial reports for axi-cel and tis-cel to observed survival from longer follow-up clinical trial reports [66,67]. In addition to extended clinical trial data, real-world observational data could also be used to confirm extrapolation techniques.…”

Section: Opportunities For Future Researchmentioning

confidence: 99%

See 1 more Smart Citation

Applying State-of-the-Art Survival Extrapolation Techniques to the Evaluation of CAR-T Therapies: Evidence from a Systematic Literature Review

et al. 2021

View full text Add to dashboard Cite

Introduction: Traditional statistical techniques for extrapolating short-term survival data for anticancer therapies assume the same mortality rate for noncured and ''cured'' patients, which is appropriate for projecting survival of non-curative therapies but may lead to an underestimation of the treatment effectiveness for potentially curative therapies. Our objective was to ascertain research trends in survival extrapolation techniques used to project the survival benefits of chimeric antigen receptor T cell (CAR-T) therapies. Methods: A global systematic literature search produced a review of survival analyses of CAR-T therapies, published between January 1, 2015 and December 14, 2020, based on publications sourced from MEDLINE, scientific conferences, and health technology assessment agencies. Trends in survival extrapolation techniques used, and the rationale for selecting advanced techniques, are discussed.

show abstract

Section: Opportunities For Future Researchmentioning

confidence: 99%

Section: Opportunities For Future Researchmentioning

confidence: 99%

Applying State-of-the-Art Survival Extrapolation Techniques to the Evaluation of CAR-T Therapies: Evidence from a Systematic Literature Review

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Interestingly, about 90% of patients had polyclonal B-cell recovery (including memory B-cells) and 60% of responding patients still had CAR+ T cells detected in blood, similar to the NCI experience. 58…”

Section: Clinical Experience With Axi-celmentioning

confidence: 99%

The role of axicabtagene ciloleucel as a treatment option for patients with follicular/marginal zone lymphoma

Sandoval-Sus

Chávez

2021

Therapeutic Advances in Hematology

View full text Add to dashboard Cite

Chimeric antigen receptor (CAR) T-cell therapy with axicabtagene ciloleucel (axi-cel) continues to make its way in the treatment of B-cell lymphomas. Follicular lymphoma (FL) is the second most common non-Hodgkin’s lymphoma. While its prognosis is usually good, the disease is considered incurable and patients still relapse. High-risk subgroups such as high FLIPI score or early relapses (POD24) face poor outcomes. Current treatment options with phosphatidylinositol 3-kinase (Pi3K) inhibitors or other novel agents have clinical activity but short remission with cures remaining elusive. The ZUMA-5 study of axi-cel has shown high response rates with durable remissions with manageable toxicities, particularly in poor risk FL, replicating the outcomes in smaller and earlier studies. Long-term follow up will demonstrate the real impact of axi-cel in relapsed FL.

show abstract

“…The latest long-term follow-up from the ZUMA-1 study (median follow-up 39.1 months) was presented at the ASH annual meeting in 2020 and reported durable responses with 47% 3 years overall survival. 20 Tisagenlecleucel is a second-generation anti-CD19 CAR-T construct that is commercially available for use in patients with relapsed/refractory DLBCL following at least two lines of prior therapy. In the phase 2 JULIET study, 93 relapsed/refractory DLBCL patients received tisagenlecleucel infusion.…”

Section: Car-t Cells In Clinical Trials For Lymphomamentioning

confidence: 99%

A Review of Chimeric Antigen Receptor T-Cell Therapy for Myeloma and Lymphoma

Atrash¹,

Moyo²

2021

OTT

View full text Add to dashboard Cite

Collectively, hematological malignancies account for the fourth most common malignancy. Myeloma and lymphoma are the most common types of hematological malignancies. Unfortunately, the management of refractory myeloma and lymphoma remains challenging. The discovery of new immunological therapies, namely chimeric antigen receptors T cells (CAR-T), outlined unprecedented B cell malignancies results. In this context, the CAR-T-based approach has led to the proliferation of many clinical studies. In this review, we will deal with the CAR-T structure, and we will summarize the primary clinical studies assessing the risks and benefits of CAR-T cell therapy. We will also deal with the adverse events and management of cytokine release syndromes/immune effector cell-associated neurotoxicity syndrome (ICANS). Subsequently, we will review potential future improvements to overcome refractoriness and improve expansion while decreasing CAR-T’s off-target effects. The advances in the CAR-T platform represent a step forward with promising unlimited future possibilities that made it a paradigm-shifting for the management of B cell malignancies.

show abstract

Long-Term Survival and Gradual Recovery of B Cells in Patients with Refractory Large B Cell Lymphoma Treated with Axicabtagene Ciloleucel (Axi-Cel)

Cited by 26 publications

References 0 publications

Applying State-of-the-Art Survival Extrapolation Techniques to the Evaluation of CAR-T Therapies: Evidence from a Systematic Literature Review

Applying State-of-the-Art Survival Extrapolation Techniques to the Evaluation of CAR-T Therapies: Evidence from a Systematic Literature Review

The role of axicabtagene ciloleucel as a treatment option for patients with follicular/marginal zone lymphoma

A Review of Chimeric Antigen Receptor T-Cell Therapy for Myeloma and Lymphoma

Contact Info

Product

Resources

About